首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Incomplete radiofrequency ablation promotes the development of CD133+ cancer stem cells in hepatocellular carcinoma cell line HepG2 via inducing SOX9 expression
【24h】

Incomplete radiofrequency ablation promotes the development of CD133+ cancer stem cells in hepatocellular carcinoma cell line HepG2 via inducing SOX9 expression

机译:射频不完全消融通过诱导SOX9表达促进肝癌细胞HepG2中CD133 +癌症干细胞的发育

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Cancer stem cells (CSCs) accelerate the growth of hepatocellular carcinoma (HCC) residual after incomplete radiofrequency ablation (In-RFA). The present study aimed to detect the effects of In-RFA on stemness transcription factors (STFs) expression which are important for the production and function of CSCs, and to find which STFs promote HCC stemness after In-RFA. Methods: HepG2 cells were used for in vitro and in vivo studies. Flow cytometry and sphere-formation assays were used to detect the level and function of CD133+CSCs in the models. PCR array and ELISA were applied to analyze the altered expression of 84 STFs in CD133+CSCs in two models. Specific lentiviral shRNA was used to knockdown STFs expression, followed by detecting In-RFA's effects on the levels and function of CD133+CSCs. Results: In-RFA was identified to induce CD133+CSCs and increase their tumorigenesis ability in vitro and in vivo. The mRNA levels of 84 STFs in CD133+CSCs were detected by PCR array, showing that 15 and 22 STFs were up-regulated in two models, respectively. Meanwhile, the mRNA levels of seven common STFs were up-regulated in both models. ELISA assay demonstrated that only the protein of sex determin-ing region Y-box 9 (SOX9) was up-regulated in both models, the protein levels of the other 6 common STFs did not increase in both models. Finally, SOX9 was identified to play an important role in inducing, maintaining stemness and promoting tumorigenesis ability of CD133+CSCs in both models. Conclusion: In-RFA-induced SOX9 stimulates CD133+CSCs proliferation and increases their tumorigenesis ability, suggesting that SOX9 may be a good target for HCC treatment.
机译:背景:癌干细胞(CSC)加速射频消融(In-RFA)后残留的肝细胞癌(HCC)的生长。本研究旨在检测In-RFA对干细胞转录因子(STFs)表达的影响,这对于CSC的产生和功能很重要,并寻找哪些STF在In-RFA后促进HCC干细胞。方法:HepG2细胞用于体外和体内研究。流式细胞仪和球形成测定法用于检测模型中CD133 + CSC的水平和功能。应用PCR芯片和酶联免疫吸附试验(ELISA)分析两种模型中CD133 + CSCs中84个STF的表达变化。使用特定的慢病毒shRNA敲低STF的表达,然后检测In-RFA对CD133 + CSCs的水平和功能的影响。结果:In-RFA在体外和体内均可诱导CD133 + CSCs并增强其肿瘤发生能力。通过PCR芯片检测CD133 + CSCs中84个STF的mRNA水平,表明在两个模型中分别有15个和22个STF被上调。同时,两种模型中七个常见STF的mRNA水平均被上调。 ELISA分析表明,在两个模型中仅性别决定区域Y-box 9(SOX9)的蛋白被上调,其他六个常见STF的蛋白水平在两个模型中均未增加。最后,在两个模型中,SOX9被鉴定在诱导,维持干性和促进CD133 + CSCs的肿瘤发生能力中起重要作用。结论:In-RFA诱导的SOX9刺激CD133 + CSCs增殖并增强其肿瘤发生能力,表明SOX9可能是HCC治疗的良好靶标。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2018年第005期|416-422|共7页
  • 作者单位

    Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;

    Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China;

    Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;

    Beijing Institute of Hepatology, Beijing 100069, China;

    Beijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing 100069, China;

    Department of Biochemistry and Molecular Biology, Baotou Medical College, Baotou 014040, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 04:27:24
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号